Orris

Clopidogrel 5 mark answer

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Searching Images

clopidogrel mechanism ADP P2Y12 platelet inhibition prodrug

I now have comprehensive information from multiple authoritative sources. Let me compile the complete 5-mark answer.

Clopidogrel

Drug Class & Overview

Clopidogrel is a thienopyridine antiplatelet drug belonging to the P2Y12 ADP receptor antagonist class. It is one of the most widely used antiplatelet agents in cardiovascular medicine.

Mechanism of Action

Clopidogrel is a prodrug that requires hepatic biotransformation via the cytochrome P450 enzyme CYP2C19 to generate its active metabolite. This active thiol metabolite irreversibly blocks the ADP P2Y12 receptor on platelets. Blockade of this receptor:
  • Prevents ADP-induced platelet activation and aggregation
  • Inhibits fibrinogen binding to glycoprotein IIb/IIIa
  • Has no effect on prostaglandin metabolism (unlike aspirin)
Because the blockade is irreversible, the antiplatelet effect lasts for the entire platelet lifespan (7-10 days).

Pharmacokinetics

ParameterDetail
RouteOral (prodrug)
ActivationCYP2C19 in liver (two-step oxidation)
OnsetLoading dose: inhibition in ~2-5 hours; maintenance: steady state in ~3-7 days
Half-lifeActive metabolite ~30 minutes (but platelet effect irreversible)
Duration7-10 days after stopping
Excretion~50% urine, ~50% feces
After a 300-mg loading dose, 80% platelet inhibition is achieved within 5 hours. The standard maintenance dose is 75 mg/day orally.

Approved Indications

  1. Acute Coronary Syndromes (ACS) - Unstable angina / NSTEMI: in combination with aspirin (dual antiplatelet therapy, DAPT); loading dose 300 mg, then 75 mg/day
  2. STEMI - 75 mg/day with aspirin
  3. Coronary artery stenting - DAPT to prevent stent thrombosis (duration depends on stent type)
  4. Recent MI, stroke, or established peripheral arterial disease - 75 mg/day as secondary prevention
  5. Ischemic stroke / TIA - as an alternative to aspirin (CAPRIE trial: clopidogrel vs. aspirin)

Adverse Effects

  • Bleeding - most common serious effect; major bleeding ~2%/year; increased with aspirin co-administration
  • Thrombotic thrombocytopenic purpura (TTP) - rare but life-threatening
  • Neutropenia / agranulocytosis - rare (less frequent than ticlopidine)
  • Rash, diarrhea, dyspepsia - minor GI effects
  • Clopidogrel is generally better tolerated than its predecessor ticlopidine

Clopidogrel Resistance

Resistance is defined as failure to adequately inhibit platelet aggregation despite therapy. Causes include:
  1. Genetic polymorphisms in CYP2C19 - "Poor metabolizers" (CYP2C19 loss-of-function alleles such as *2 and *3) cannot adequately activate clopidogrel, leading to inadequate platelet inhibition and increased cardiovascular risk. The FDA recommends CYP2C19 genotyping to identify such patients and considering alternatives (prasugrel, ticagrelor) in poor metabolizers.
  2. Drug interactions - PPIs (omeprazole, esomeprazole) inhibit CYP2C19 and reduce clopidogrel activation. Atorvastatin (CYP3A4 competition) may also reduce efficacy.
  3. Clinical factors - poor compliance, diabetes, obesity, increased platelet turnover

Important Drug Interaction: Clopidogrel + PPIs

PPIs such as omeprazole and esomeprazole competitively inhibit CYP2C19, significantly reducing the formation of clopidogrel's active metabolite and thus its antiplatelet efficacy. This is clinically relevant in patients on dual antiplatelet therapy. Pantoprazole has the least interaction. - Lippincott Illustrated Reviews: Pharmacology; Goodman & Gilman's

Comparison with Related Drugs

FeatureClopidogrelPrasugrelTicagrelor
ClassThienopyridineThienopyridineCyclopentyl-triazolopyrimidine
Prodrug?Yes (CYP2C19)Yes (less dependent on CYP2C19)No (direct acting)
ReversibilityIrreversibleIrreversibleReversible
OnsetSlowerFasterFastest
CYP2C19 effectSignificantMinimalNot applicable
Bleeding riskModerateHigher (avoid in >75 yrs, prior stroke)Moderate-high

Key Clinical Trials

  • CAPRIE trial: Clopidogrel vs. aspirin in patients with recent MI, stroke, or PAD - clopidogrel reduced cardiovascular death, MI, and stroke by 8.7% compared to aspirin
  • CURE trial: Clopidogrel + aspirin vs. aspirin alone in unstable angina - combination reduced CV events by 20% (9.3% vs. 11.4%) but increased major bleeding
  • TRITON-TIMI 38: Prasugrel vs. clopidogrel in ACS - prasugrel superior for efficacy but with higher bleeding risk

Key Points Summary

  1. Clopidogrel is a thienopyridine prodrug → activated by CYP2C19 → irreversibly blocks P2Y12 ADP receptor on platelets
  2. Dose: 300-600 mg loading, then 75 mg/day maintenance
  3. Duration of effect: 7-10 days (platelet lifespan)
  4. Major concern: CYP2C19 polymorphism causing resistance; PPI interaction (especially omeprazole)
  5. Used in ACS, post-stent, stroke/TIA, PAD - often as DAPT with aspirin
  6. Adverse effects: bleeding, rare TTP, neutropenia
  7. Preferred over ticlopidine due to better safety profile
Sources: Katzung's Basic and Clinical Pharmacology (16th ed.), Braunwald's Heart Disease (Cardiovascular Medicine), Lippincott Illustrated Reviews: Pharmacology, Goodman & Gilman's Pharmacological Basis of Therapeutics
This is a shared conversation. Sign in to Orris to start your own chat.